探讨瑞马唑仑与瑞芬太尼用于胃镜下黏膜剥离术的效果

Abstract: Objective To investigate the efficacy of remimazolam combined with remifentanil in endoscopic submucosal dissection. Methods A total of 88 patients undergoing endoscopic submucosal dissection in our hospital were enrolled between October 2022 and March 2025, 44 cases were included in the experimental group by the envelope method, and the remaining 44 cases were included in the reference group. The same anesthesia induction protocol was provided for both groups of patients. On this basis, remimazolam combined with remifentanil was added to the experimental group, and remifentanil was added to the reference group. The two groups were compared in vital signs, analgesia and anesthesia recovery, stress response, state of consciousness, cognitive function and safety. Results Post-anesthesia induction, the experimental group demonstrated superior vital signs compared to the reference group. The reference group exhibited poorer analgesia and anesthesia recovery outcomes than the experimental group. Postoperative stress response indicators showed better results in the experimental group. After the operation, the consciousness status and cognitive function of the experimental group were better than those of the reference group. Safety profiles also indicated superiority in the experimental group (P＜0.05). Conclusion The application of remimazolam combined with remifentanil in endoscopic submucosal dissection surgery helps maintain stable vital signs, enhance analgesia and anesthesia recovery, reduce stress responses, improve the state of consciousness, reduce the risk of postoperative cognitive impairment and improve safety.